Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold
- 1 October 2008
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (19) , 5259-5262
- https://doi.org/10.1016/j.bmcl.2008.08.077
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptorBioorganic & Medicinal Chemistry Letters, 2008
- Molecular features crucial to the activity of pyrimidine benzamide-based thrombopoietin receptor agonistsBioorganic & Medicinal Chemistry Letters, 2008
- Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic PurpuraNew England Journal of Medicine, 2007
- Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis CNew England Journal of Medicine, 2007
- Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonistBlood, 2007
- EltrombopagDrugs of the Future, 2006
- Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonistExperimental Hematology, 2005
- Photoactivated enediynes: targeted chimeras which undergo photo-Bergman cyclizationTetrahedron Letters, 2004
- Hydrazinonaphthalene and Azonaphthalene Thrombopoietin Mimics Are Nonpeptidyl Promoters of MegakaryocytopoiesisJournal of Medicinal Chemistry, 2001
- New isoquinolines as potential bronchodilator agentsTetrahedron, 1973